Need Help?

Genomic characterization of Malignant Pleural Mesothelioma.

Genomic characterization of Malignant Pleural Mesothelioma using RNA-seq, Exome and Illumina 2.5 M array.

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID Description Technology Samples
EGAD00001001913 Illumina HiSeq 2500 198
EGAD00001001914 Illumina HiSeq 2000 12
EGAD00001001915 Illumina HiSeq 2000 211
EGAD00001001916 Illumina HiSeq 2000 207
EGAD00001001917 PacBio RS II 1
Publications Citations
Genomics and Epigenetics of Malignant Mesothelioma.
High Throughput 7: 2018 E20
Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications.
Nat Commun 10: 2019 1333
Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interactions.
EBioMedicine 48: 2019 191-202
Integrated genomics point to immune vulnerabilities in pleural mesothelioma.
Sci Rep 11: 2021 19138
A combination of intrinsic and extrinsic features improves prognostic prediction in malignant pleural mesothelioma.
Br J Cancer 127: 2022 1691-1700
Artificial Intelligence Techniques to Predict the Airway Disorders Illness: A Systematic Review.
Arch Comput Methods Eng 30: 2023 831-864
Heterogeneous RNA editing and influence of ADAR2 on mesothelioma chemoresistance and the tumor microenvironment.
Mol Oncol 16: 2022 3949-3974
Preclinical evaluation of CDK4 phosphorylation predicts high sensitivity of pleural mesotheliomas to CDK4/6 inhibition.
Mol Oncol 18: 2024 866-894
Viral Mimicry Response Is Associated With Clinical Outcome in Pleural Mesothelioma.
JTO Clin Res Rep 3: 2022 100430
A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma.
Clin Cancer Res 29: 2023 548-559
Genetic screens reveal new targetable vulnerabilities in BAP1-deficient mesothelioma.
Cell Rep Med 4: 2023 100915
YAP/TAZ activation predicts clinical outcomes in mesothelioma and is conserved in in vitro model of driver mutations.
Clin Transl Med 13: 2023 e1190
The Pattern of RNA Editing Changes in Pleural Mesothelioma upon Epithelial-Mesenchymal Transition.
Int J Mol Sci 24: 2023 2874
Multiomic analysis of malignant pleural mesothelioma identifies molecular axes and specialized tumor profiles driving intertumor heterogeneity.
Nat Genet 55: 2023 607-618
A Novel Two-Gene Expression-Based Prognostic Score in Malignant Pleural Mesothelioma.
Diagnostics (Basel) 13: 2023 1556
Clonal gene signatures predict prognosis in mesothelioma and lung adenocarcinoma.
NPJ Precis Oncol 8: 2024 47
The MexTAg collaborative cross: host genetics affects asbestos related disease latency, but has little influence once tumours develop.
Front Toxicol 6: 2024 1373003